Nov 19, 2021
Penn State Health Milton S. Hershey Medical Center implements new, collaborative postoperative standardizations to improve outcomes for urologic surgery patients, including shorter hospital stays and fewer readmissions.
At Penn State Cancer Institute, the increased adoption of active surveillance for prostate cancer patients is yielding positive outcomes while deferring or eliminating the negative side effects of treatment.
The ALS Clinic at Penn State Health Milton S. Hershey Medical Center has enrolled 21 patients thus far in the HEALEY ALS Platform Trial, a unique multistate, multi-center study.
Neurosurgeons at Penn State Health Milton S. Hershey Medical Center use the optical imaging agent Gleolan to confirm the presence of a glioma brain tumor, enabling them to remove more malignant tissue. Gleolan attaches to the brain tumor and fluoresces.
Aug 24, 2021
A unique trial allows Penn State Health Milton S. Hershey Medical Center patients with fistulas due to Crohn’s disease access to a leading-edge stem cell clinical trial.
Aug 9, 2021
A retrospective study of 117 adult acute ischemic stroke patients who underwent mechanical thrombectomy shows that individual instances of elevated systolic blood pressure can significantly affect clinical outcomes.
Researchers at Penn State Health and Penn State College of Medicine will test whether KCZ and PCZ can block the hexokinase 2 enzyme, believed to be a factor in the aggressiveness of high-grade gliomas.
A long-term analysis of 36 patients treated in the Chemotherapy for Ablation and Resolution of Mucinous pancreatic cysts (CHARM) trial shows the durability of complete cyst resolution after endoscopic ultrasound-guided chemoablation with paclitaxel and gemcitabine.
A retrospective study of thyroid cancer cases reported in the Nurses Health Study II shows that women who entered menopause at age 45 or older had a higher risk of thyroid cancer compared with women who entered menopause at a younger age.
Jul 14, 2021
Researchers at Penn State Cancer Institute have begun a three-year study aimed at identifying the next generation of predictive biomarkers and immune oncology-based treatment for bladder cancer, a condition that commonly affects military veterans.
